IBT
REGN icon

International Biotechnology Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

International Biotechnology Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$7.28M Sell
8,847
-18,153
-67% -$14.3M 2.45% 16
2023
Q2 		$19.4M Buy
27,000
+15,800
+141% +$12.2M 5.91% 4
2023
Q1 		$9.2M Hold
11,200
– – 2.57% 13
2022
Q4 		$8.08M Hold
11,200
– – 2.5% 14
2022
Q3 		$7.71M Sell
11,200
-2,810
-20% -$1.77M 2.47% 13
2022
Q2 		$23.7K Buy
14,010
+1,910
+16% +$1.24M 0.25% 61
2022
Q1 		$2.25M Hold
12,100
– – 0.51% 41
2021
Q4 		$7.64M Buy
12,100
+4,400
+57% +$2.71M 1.7% 23
2021
Q3 		$4.66M Sell
7,700
-29,500
-79% -$18.3M 1.12% 26
2021
Q2 		$20.8M Sell
37,200
-6,600
-15% -$3.34M 5.49% 5
2021
Q1 		$20.7M Buy
43,800
+32,300
+281% +$15.7M 5.48% 3
2020
Q4 		$5.55M Hold
11,500
– – 1.52% 19
2020
Q3 		$6.43M Hold
11,500
– – 2.08% 18
2020
Q2 		$7.02M Buy
+11,500
New +$6.53M 2.33% 17
2020
Q1 		– Sell
-28,830
Closed -$10.8M – 62
2019
Q4 		$10.8M Sell
28,830
-11,000
-28% -$3.7M 3.9% 8
2019
Q3 		$11.1M Buy
39,830
+16,500
+71% +$4.88M 5.11% 6
2019
Q2 		$7.3M Sell
23,330
-8,300
-26% -$2.76M 2.71% 14
2019
Q1 		$13M Buy
31,630
+300
+1% +$124K 4.8% 3
2018
Q4 		$9.19M Hold
31,330
– – 5.7% 5
2018
Q3 		$9.71M Hold
31,330
– – 4.61% 6
2018
Q2 		$10.8M Sell
31,330
-4,700
-13% -$1.47M 4.15% 6
2018
Q1 		$12.4M Sell
36,030
-4,800
-12% -$1.67M 4.84% 6
2017
Q4 		$15.4M Hold
40,830
– – 5.41% 3
2017
Q3 		$18.3M Sell
40,830
-7,300
-15% -$3.47M 7.11% 3
2017
Q2 		$23.6M Buy
48,130
+3,000
+7% +$1.31M 8.98% 1
2017
Q1 		$17.5M Buy
45,130
+12,700
+39% +$4.71M 6.69% 3
2016
Q4 		$11.9M Buy
+32,430
New +$12.3M 5.37% 7

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

International Biotechnology Trust's REGN Position: Q3 2023 in Review

International Biotechnology Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 67% in Q3 2023, selling an estimated $14.3M and leaving 8,847 shares worth $7.28M. The position accounts for 2.45% of the portfolio, ranked #16.

International Biotechnology Trust first reported a position in REGN in Q4 2016 and has held it in 27 quarters since. The position peaked at $23.6M in Q2 2017. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • International Biotechnology Trust held 8,847 shares of Regeneron Pharmaceuticals worth $7.28M as of Q3 2023.
  • International Biotechnology Trust sold 18,153 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $14.3M.
  • Regeneron Pharmaceuticals made up 2.45% of International Biotechnology Trust's portfolio in Q3 2023, its #16 holding.
  • International Biotechnology Trust first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 27 quarters since.
  • International Biotechnology Trust's Regeneron Pharmaceuticals position peaked at $23.6M in Q2 2017.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.